Study directory

ADHD studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
1740studies shown
Showing 445-456 of 1,740
Drug study icon
CompletedEUCTR 2011-004668-31

A Phase 3, Open-label, Multicentre, Protocol to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participat...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about ADHD.

ADHDDrugA study involving a medication or substance.
Countries
United Kingdom, Belgium, Austria, ...
Sponsor
Shire Pharmaceutical Development Ltd
Condition
ADHD
Drug study icon
CompletedEUCTR 2010-020951-30

A Phase 4, Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents Aged 6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
United Kingdom, Belgium, Germany, ...
Sponsor
Shire Pharmaceutical Development Ltd
Condition
ADHD
Drug study icon
CompletedEUCTR 2004-003941-42

A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and ...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Sweden
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
Sweden
Sponsor
Eli Lilly Sweden AB
Condition
ADHD
Biological study icon
TerminatedEUCTR 2016-000215-32

Effect of Pycnogenol® on Attention-Deficit Hyperactivity Disorder (ADHD): A randomized, double blind, placebo and active product controlled multicenter trial.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about ADHD.

ADHDBiological
Countries
Belgium
Sponsor
University of Antwerp
Condition
ADHD
Biological study icon
CompletedEUCTR 2016-002171-94

Effectiveness of a personalized Neurofeedback Training device (ADHD@Home) as compared with Methylphenidate in the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about ADHD.

ADHDBiological
Countries
Belgium, Spain
Sponsor
Mensia Technologies SA
Condition
ADHD
Drug study icon
CompletedEUCTR 2010-024551-82

OPEN LABEL TRIAL OF ATOMOXETINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN WITH 22q11.2 DELETION SYNDROME (22qDS)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
United Kingdom
Sponsor
King's College London [...] 1. King's College London 2. South London and Maudsley NHS Foundation Trust
Condition
ADHD
Drug study icon
CompletedEUCTR 2008-004827-44

OPEN LABEL TRIAL OF ATOMOXETINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN WITH SPECIAL EDUCATIONAL NEEDS

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
United Kingdom
Sponsor
King's College London
Condition
ADHD
Drug study icon
CompletedEUCTR 2007-007672-41

Protocol B4Z-MC-LYDO(b) Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Cont...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
France, United Kingdom, Belgium, ...
Sponsor
Eli Lilly and Company
Condition
ADHD
Drug study icon
CompletedEUCTR 2015-004271-78

Randomised controlled trial of the short term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
United Kingdom
Sponsor
King's College London
Condition
ADHD
Behavioral study icon
Not recruitingISRCTN73911400

Effectiveness of parent management training in ADHD

This study is not recruiting in Germany. It is testing parent management training for ADHD.

In Germany
Why is this study shown?

This study is directly about ADHD.

ADHDOther
Countries
Germany
Sponsor
Wuerzburg University Hospital (Germany)
Condition
ADHD
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.